使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to Twist Biosciences 2026 second quarter financial results conference call. (Operator Instructions) Also note, this call is being recorded. I would now like to turn the call over to Angela Bitting, SVP of Corporate Affairs. Please go ahead.
歡迎收聽 Twist Biosciences 2026 會計年度第二季財務業績電話會議。(接線員指示)另外提醒,本通話將被錄音。我現在想把電話交給企業事務資深副總裁 Angela Bitting。請開始。
Angela Bitting - Senior Vice President - Corporate Affairs; Chief Corporate Responsibility Officer
Angela Bitting - Senior Vice President - Corporate Affairs; Chief Corporate Responsibility Officer
Thank you, operator. Good morning, everyone. I would like to thank you for joining us for Twist Biosciences conference call to review our fiscal 2026 second quarter financial results and business progress. We issued our financial results press release before the market, and it is available at our website at www.twistbiocience.com. With me on the call today tare Dr. Emily Leproust, CEO and Co-Founder of Twist; Adam Laponis, CFO of Twist; and Dr. Patrick Finn, President and COO of Twist.
謝謝,接線員。各位早安。感謝各位參加 Twist Biosciences 的電話會議,一同回顧我們 2026 會計年度第二季的財務業績與業務進展。我們已於開盤前發布財務業績新聞稿,並已上傳至我們的網站 www.twistbiocience.com。今天與我一同在線上的有 Twist 執行長暨共同創辦人 Emily Leproust 博士、Twist 財務長 Adam Laponis,以及 Twist 總裁暨營運長 Patrick Finn 博士。
Today, we will discuss our business progress, financial and operational performance as well as growth opportunities. We will then open the call for questions. We ask that you limit your questions to only one, and then requeue as a courtesy to others on the call. This call is being recorded. The audio portion will be archived in the Investors Section of our website and will be available for two weeks.
今天我們將討論業務進展、財務與營運表現,以及成長機會。之後我們將開放提問。我們請各位每次僅提一個問題,之後再重新排隊,以禮讓其他與會者。本通話正在錄音。音訊內容將存檔於我們網站的投資人專區,並提供兩週的收聽期限。
During today's presentation, we will make forward-looking statements in the meaning of the US federal securities laws. Forward-looking statements generally relate to future events or future financial or operating performance. Our expectations and beliefs regarding these matters may not materialize, and actual results and financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected. These risks include those set forth in the press release we issued earlier today as well as those more fully described in our filings with the Securities and Exchange Commission. The forward-looking statements in this presentation are based on information available as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.
在今天的簡報中,我們將依據美國聯邦證券法的定義提出前瞻性陳述。前瞻性陳述通常與未來事件或未來財務或營運表現相關。我們對這些事項的預期與信念可能無法實現,實際結果與財務期間亦可能受到風險與不確定性影響,導致實際結果與預測有重大差異。這些風險包括我們今日稍早發布之新聞稿所載者,以及我們向美國證券交易委員會提交文件中更完整描述者。本簡報中的前瞻性陳述係基於截至本日可得之資訊,除法律要求外,我們不承擔更新任何前瞻性陳述之義務。
We'll also discuss adjusted EBITDA, a financial measure that does not conform with generally accepted accounting principles. Information may be calculated differently than similar not update presented by other companies. When reported, a reconciliation between GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on the Investors section of our website.
我們也將討論調整後 EBITDA,這是一項不符合一般公認會計原則(GAAP)的財務衡量指標。其計算方式可能與其他公司所呈現的類似指標不同。於我們揭露時,GAAP 與非 GAAP 財務衡量指標之間的調節表將包含在我們的財報文件中,並可於我們網站的投資人專區查閱。
With that, I will now turn the call over to our CEO and Co-Founder, Emily Leproust.
接下來,我將把電話交給我們的執行長暨共同創辦人 Emily Leproust。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you, Angela, and good morning, everyone. Twist delivered another strong quarter and extended our track record of consistent execution, posting our 13th quarter of sequential revenue growth. We have outperformed the broader license tools market with a model that scales efficiently and drive increasing value creation.
謝謝你,Angela,各位早安。Twist 本季再度交出強勁表現,並延續我們一貫穩健執行的紀錄,達成連續第 13 季營收季增。我們以可高效率擴張的商業模式,帶動價值創造持續提升,表現優於更廣泛的生命科學工具市場。
Twist core technology advantage is a semiconductor-based D&A platform that provides a structural advantage in cost, scale and speed that feeds into every product and service we offer. This same platform also enables a highly efficient new product introduction engine, allowing us to rapidly translate customer demand into scalable offerings and continuously expand our portfolio.
Twist 的核心技術優勢在於以半導體為基礎的 DNA 平台,於成本、規模與速度上具備結構性優勢,並滲透到我們提供的每一項產品與服務。相同的平台也支援高度高效率的新產品導入引擎,使我們能快速將客戶需求轉化為可規模化的產品,並持續擴充產品組合。
As we increase volume on the silicon chip, we expand our wallet share, accelerate product innovation and further strengthen our competitive advantage. The model works exactly as designed. We have delivered sustained revenue growth, expanded margin above 50%, invested strategically to drive continued return on that investment, and we remain firmly on track to achieve adjusted EBITDA breakeven in the fourth quarter of fiscal 2026.
隨著我們在矽晶片上的產量提升,我們擴大客戶錢包占比、加速產品創新,並進一步強化競爭優勢。這個模式完全如設計般運作。我們已實現持續的營收成長、將毛利率擴張至 50% 以上,並進行策略性投資以帶動投資報酬持續回收;同時,我們仍堅定朝向在 2026 會計年度第四季達成調整後 EBITDA 損益兩平的目標前進。
Focusing our results for the second quarter of fiscal 2026, we grew total revenue to $110.7 million, up more than 19% year-over-year. DNA synthesis and Protein Solutions grew 28%, powered by continued strength in AI-enabled drug discovery, NHS applications grew 12% year-over-year and 9% sequentially.
聚焦 2026 會計年度第二季的成果,我們的總營收成長至 1.107 億美元,年增超過 19%。DNA 合成與蛋白質解決方案成長 28%,主要受 AI 賦能藥物探索持續強勁所帶動;NHS 應用年增 12%,且季增 9%。
Diving deeper into DNA synthesis and Protein Solutions, we continue to see robust growth. Last month, Amazon Web Services announced Twist as a wet lab partner for Amazon BioDiscovery it's AI-powered drug discovery application. This is an exciting validation of our DNA synthesis, protein solutions and biologics capabilities.
進一步看 DNA 合成與蛋白質解決方案,我們持續看到強勁成長。上個月,Amazon Web Services 宣布 Twist 成為 Amazon BioDiscovery(其 AI 驅動的藥物探索應用)的濕實驗室合作夥伴。這是對我們 DNA 合成、蛋白質解決方案與生物製劑能力的一項令人振奮的肯定。
In advance of the launch, Twist has been working with AWS team for several months providing web lab services for the applications scientific launch partners, including Memorial Sloan Kettering Cancer Center and the GRAIL Lab adjuncts of (inaudible). The objective for researchers using Amazon BioDiscovery is to deploy AI models to design and optimize antibody candidates faster. We are here to support them with products and services that accelerate that pathway. I think in close contact with our customers, we identified this emerging category of AI near early and invested ahead of the market acceleration with increasing adoption across pharma, drylab and big tech companies.
在正式推出之前,Twist 已與 AWS 團隊合作數月,為該應用的科學啟動合作夥伴提供濕實驗室服務,其中包括 Memorial Sloan Kettering Cancer Center 以及(聽不清)之 GRAIL 實驗室附屬單位。研究人員使用 Amazon BioDiscovery 的目標,是部署 AI 模型以更快設計並優化抗體候選物。我們在此以產品與服務支持他們,加速這一路徑。我認為,透過與客戶的密切互動,我們很早就辨識出這個新興的 AI 類別,並在市場加速前提前投入;目前在製藥公司、乾實驗室與大型科技公司之間的採用正持續增加。
Importantly and unbalanced, the growth of AI enabled discoveries complements our work with customers pursuing traditional discovery, which remains a robust area of our business. Regardless of approach, our customers for DNA synthesis and Protein solutions are all working through the same fundamental design build test learn cycle.
重要的是,且不失衡地,AI 賦能探索的成長與我們協助客戶進行傳統探索的工作相互補強;傳統探索仍是我們業務中相當穩健的一部分。無論採用何種方法,我們 DNA 合成與蛋白質解決方案的客戶都在同一個基本的「設計-建構-測試-學習」循環中運作。
What differs is how they execute against that framework. There is no one-size-fit-all model model. Each program is tailored to the customer scientific resources and stage of discovery, but remains constant across every engagement is the foundation Twist silicon platform, which enables cost-effective synthesis of hundreds of thousands of unique sequences in parallel. That unique and proprietary capability is what makes speed at scale possible, no matter where the customer enters the workflow. No two orders are identical, so we see consistent patterns in how these campaigns are structured.
不同之處在於他們如何在該框架下執行。並不存在一體適用的模式。每個專案都會依客戶的科學資源與探索階段量身打造;但在每一次合作中不變的是 Twist 矽基平台的基礎,它能以平行方式、具成本效益地合成數十萬條獨特序列。這項獨特且專有的能力,使「規模化的速度」成為可能,無論客戶從工作流程的哪個環節切入皆然。由於沒有兩筆訂單完全相同,我們也看到這些專案在結構安排上呈現一致的模式。
On slide 6, to give you some context. One example is our work with Memorial Sloan Ketterings and Amazon, where the team ordered approximately 100,000 specific DNA sequences as a pool labor. This approach is highly efficient and precisely because of how our platform is built. (inaudible) DNA can be manufactured electively rather than individually cloned and processed, driving on cost of sequence dramatically. And Twist is a unique provider, we can deliver hundreds of thousands of specific sequences pooled at speed and scale.
在第 6 張投影片上,提供一些背景脈絡。其中一個例子是我們與 Memorial Sloan Kettering 及 Amazon 的合作,團隊以「池化文庫」的形式訂購了約 100,000 條特定 DNA 序列。這種方法非常高效率,正是因為我們平台的建構方式。(聽不清)DNA 可以以選擇性方式製造,而非逐一克隆並處理,從而大幅降低每條序列的成本。而 Twist 是獨特的供應商,我們能以速度與規模交付池化的數十萬條特定序列。
Once there is a pooled DNA, either Twist or a customer then screens that labor to identify promising candidates, selects the most relevant sequences and advance those into individual synthesis, protein expression and characterization. Through iterative cycles, this process yields a validated antibody leads.
在取得池化 DNA 之後,Twist 或客戶會對該文庫進行篩選以找出具潛力的候選物,選出最相關的序列,並推進至單一序列合成、蛋白質表達與特性分析。透過反覆迭代循環,該流程可產出經驗證的抗體先導物。
A second model involves customers ordering hundreds to thousands of gene fragments and executing downstream workflow internally. Here again, Twist platform delivers an edge in the ability to synthesize diverse sequence sets quickly and at accessible costs, meaning customers can explore broader design spaces.
第二種模式是客戶訂購數百到數千個基因片段,並在內部執行後續工作流程。同樣地,Twist 平台在快速且以可負擔成本合成多樣化序列集合方面具備優勢,意味著客戶可以探索更廣的設計空間。
The second model involves customers ordering hundreds to thousands of fragrance and executing downstream workflow internally. Here again, Twist platform delivers an edge in the ability to synthesize diverse sequence sets quickly and at accessible costs, meaning customer connect for broader design spaces. In these cases, customers
第二種模式是客戶訂購數百到數千個片段並在內部執行後續工作流程。同樣地,Twist 平台在快速且以可負擔成本合成多樣化序列集合方面具備優勢,意味著客戶可連結並探索更廣的設計空間。在這些情況下,客戶
In these cases, customers convert fragments to clonal genes, express proteins, and perform characterization assays within their own laboratories. Others choose to start further downstream, purchasing clonal genes or antibodies and binding proteins, such as ITG SCIB, DHH and others to focus their internal efforts on functional characterization and validation.
在這些情況下,客戶會將片段轉換為克隆基因、表達蛋白質,並在其自有實驗室內進行特性分析試驗。也有客戶選擇從更下游開始,購買克隆基因或抗體與結合蛋白,例如 ITG、SCIB、DHH 等,以便將內部資源聚焦於功能性特性分析與驗證。
Even at this entry point, the advantage Twist can stream the parallel synthesis capabilities underpinning our platform and show the sequences they receive reflect the speed at scale that alternative cannot match. And we have a growing segment of customers we reliant with as an end-to-end partner. In these engagements, we entered the DNA synthesis cloning construction, protein expression and characterization. Our platform's ability to run large complex sequence sets in parallel, accelerates every stage of that workflow, and we deliver high-quality extent data that enables customers to focus on critical analysis, decision-making and iterative design.
即使在這個切入點,Twist 的優勢仍在於我們平台所支撐的平行合成能力,而客戶收到的序列也反映出替代方案無法匹敵的「規模化速度」。此外,我們也有一個持續成長的客群,將我們視為端到端合作夥伴。在這些合作中,我們涵蓋 DNA 合成、克隆建構、蛋白質表達與特性分析。我們的平台能以平行方式處理大型且複雜的序列集合,加速工作流程的每個階段;同時我們提供高品質的延伸數據,使客戶能專注於關鍵分析、決策與迭代設計。
We also have a number of customers who give us a biological target and ask us to do all of the work through in vivo, in vitro and our AI/ML discovery approaches. Across all of these models, cost scales with the scope and complexity of the workflow, ranging from smaller exploratory programs to multimillion dollar discovery efforts. Our role is to provide flexibility across the spectrum. Because our platform was purpose-built for parallel census is at scale, we can make customers where they are, whether they need a pool libraries of hundreds of thousands of sequences or a fully managed core program. We support them their research advances.
我們也有一些客戶會提供一個生物學標的,並要求我們運用 in vivo、in vitro 以及 AI/ML 探索方法完成所有工作。在所有這些模式中,成本會隨工作流程的範圍與複雜度而變動,從較小的探索性專案到數百萬美元規模的探索計畫皆有。我們的角色是提供跨整個光譜的彈性。由於我們的平台是為了大規模平行合成而量身打造,我們可以在客戶所在的位置與其合作——無論他們需要包含數十萬條序列的池化文庫,或是完全代管的核心專案。我們支持他們推進研究進展。
On slide 7, you'll see our portfolio for DNA Synthesis and Protein Solutions, serving customers across the vertical continuum. Building on our success in serving therapeutic disco customers in February, we licensed the body-bispecific platform to expand our capabilities in this rapidly growing modality. We will enable high super discovery in bispecifics, an area that is strictly been limited by scale. We have already received our first orders for this platform with a robust funnel looking forward.
在第 7 張投影片中,您將看到我們的 DNA 合成與蛋白質解決方案產品組合,服務涵蓋垂直領域的完整連續體。延續我們在服務治療性探索客戶方面的成功,我們於 2 月授權引進抗體雙特異性平台,以擴充我們在這個快速成長治療形式中的能力。我們將在雙特異性領域實現高通量探索,而該領域長期以來一直受限於規模。我們已經收到該平台的首批訂單,且未來的商機漏斗相當強勁。
Moving to slide 8 and NHS. Growth reaccelerated in the second quarter. Our NHS Trust business remains a durable and growing part of the portfolio with particular offense in oncology diagnostics. We operate at a critical part in the workflow between the sample and the sequencer, where our products support precision and customization as cap.
接著看第 8 張投影片與 NHS。第二季成長再度加速。我們的 NHS Trust 業務仍是投資組合中穩健且持續成長的一環,特別是在腫瘤診斷領域具備明顯的進攻動能。我們位於從樣本到定序儀之間的關鍵工作流程環節,產品可支援精準度與客製化,作為上限。
Our target enrichment and be preparation solutions delivered the uniformity and on-target performance required for high-sensitivity applications. This is especially relevent in the continuum of cancer care on Slide 9 where we are seeing increasing adoption in commercial diagnostic tests, including issuance molecular or minimal residual disease, or MRD. The applications demand extremely high accuracy and possibility, faster times and our chemistry is well aligned to these requirements.
我們的目標富集與文庫製備解決方案,提供高敏感度應用所需的一致性與 on-target 表現。這在第 9 張投影片所示的癌症照護連續體中特別相關;我們看到商業化診斷檢測的採用率持續提升,包括分子檢測或微小殘存病灶(MRD)。這些應用要求極高的準確度與可能性、更快的週期,而我們的化學體系與這些需求高度契合。
Specifically, on slide 10 has MRD testing transitions from early clinical adoption into scale deployment across oncology diagnostics the technical and operational requirements become significantly more demanding. These assays are pushing the limit of sensitivity, also requiring detection of Viant at extremely low allele frequencies. That places a premium on panel design as well as the entire flow to ensure uniform coverage and reposability across run. In this environment, success is on the ability to deliver highly customized target regional panels library preparation enabled by novel and lines as well as the buffer BCDRUMIs and other components optimized for specific indications and evolving clinical needs. Equally important is speed.
具體而言,在第 10 張投影片中,隨著 MRD 檢測從早期臨床採用走向在腫瘤診斷中的規模化部署,技術與營運要求顯著提高。這些檢測正推進靈敏度的極限,同時需要在極低等位基因頻率下偵測變異。這使得 panel 設計以及整體流程變得格外關鍵,以確保覆蓋度一致,並在各次 run 之間具備可重現性。在此環境下,成功取決於能否交付高度客製化的目標區域 panel 與文庫製備;這由新型酶與連接子(lines)所驅動,並搭配針對特定適應症與不斷演進的臨床需求所最佳化的 buffer、BCDRUMIs 與其他組件。同樣重要的是速度。
As these steps move into broader clinical workflows, laboratories and diagnostic developers this rapid or on panel design synthesis enrollment to support asset development panels and commercial scale up. At West, we combine high throughput DNA synthesis with precision, prop design and manufacturing at scale, enabling fast real delivery of customer panels with consistent on car statistics. That allows our customers to move quickly from development realization commercialization without compromise on data quite and importantly, securing and future-proofing the supply chain.
當這些步驟進入更廣泛的臨床工作流程時,實驗室與診斷開發者需要快速的 panel 設計、合成與導入,以支援資產開發用 panel 與商業化放量。在 West,我們結合高通量 DNA 合成與精準的 prop 設計,以及可規模化的製造能力,使客戶的 panel 能快速且如期交付,並具備一致的 on car 統計表現。這讓客戶能在不犧牲資料品質的情況下,快速從開發走向商業化;同時也能確保並為供應鏈的未來需求做好準備。
For bespoke, our tumor-informed MRD panels, like all of our NHS panels, this is a consumable-driven workflow that scales with stale volume, supporting recurring revenue as these applications extend. This time, I'd like to turn the call over to Patrick to expand further on our growth initiatives around the product offering.
對於我們的客製化、腫瘤知情(tumor-informed)MRD panels(如同我們所有 NHS panels),這是一個以耗材驅動的工作流程,會隨著檢測量擴大而擴張,並在這些應用延伸時支撐經常性收入。接下來,我想把電話會議交給 Patrick,請他進一步說明我們圍繞產品供應的成長計畫。
Patrick Finn - President, Chief Operating Officer
Patrick Finn - President, Chief Operating Officer
Thank you, Emily. Happy to our fiscal year, the results are strong, and we believe the road ahead is stronger. Everything we do in protein solutions and AI-enabled discovery runs on one foundation, our DNA synthesis platform. It's a structural advantage for cost, scale and speed, full stop. And we continue to advance and strengthen this platform to enhance customer experience even more. Today, we accept the vast majority of daily sequences as we know we can manufacture them.
謝謝你,Emily。很高興談談我們的會計年度;本期結果強勁,而我們相信前方道路更為強勁。我們在蛋白質解決方案與 AI 賦能的探索上所做的一切,都建立在同一個基礎之上:我們的 DNA 合成平台。這在成本、規模與速度上具備結構性優勢,毋庸置疑。我們也持續推進並強化這個平台,以進一步提升客戶體驗。如今,我們接受絕大多數的每日序列,因為我們知道自己能把它們製造出來。
We have an algorithm embedded in our e-commerce system to inform a customer immediately if they have uploaded a sequence that may be difficult to manufacture. Dissipation improves the user experience for customers as some sequences present manufacturing challenges, repeat regions, Herpen extreme GC content. Three years ago, we accepted about 96% of clonal genes. I could manufacture about 97.5% of clonal genes and about 98% of DNA sequences more broadly including oligo pools, DNA libraries, gene fragments. Today, we accept about 97% of clonal genes and can manufacture approximately 98.5% of clonal genes and about 99% of DNA requests more broadly.
我們在電商系統中嵌入演算法,可在客戶上傳序列後立即提示該序列是否可能難以製造。這種提前提示能改善使用者體驗,因為某些序列在製造上確實具有挑戰,例如重複區段、Herpen、或極端 GC 含量。三年前,我們大約接受 96% 的 clonal genes。我可以製造約 97.5% 的 clonal genes,且更廣泛的 DNA 序列(包括寡核苷酸池、DNA 文庫、基因片段)約可製造 98%。今天,我們約接受 97% 的 clonal genes,並可製造約 98.5% 的 clonal genes,以及更廣泛的 DNA 需求約 99%。
That's not theoretical capabilities. That's production reality at scale. We routinely deliver clonal genes and fragments up to 5,000 base fares, all the gaps up to 300 basis, novelex-gene fronts up to 500 base payers across a wide range of formats. If a customer can design it, we are increasingly able to make it. Even as the acceptance rate for DNA sequences remains very high, we recognize that in a single sequence in a larger set does not meet acceptance criteria, customers may choose to route the full set elsewhere. This dynamic highlights a clear opportunity. Continued improvements in acceptance rates can unlock incremental share gains and expand total order capture.
這不是理論能力,而是規模化量產的現實。我們例行性交付長度最高達 5,000 個鹼基的 clonal genes 與片段、所有 gaps 最高達 300 個 basis、novelex-gene fronts 最高達 500 個 base payers,涵蓋多種格式。只要客戶能設計出來,我們就愈來愈能把它做出來。即使 DNA 序列的接受率仍然非常高,我們也意識到:在一組較大的序列集合中,只要有單一序列不符合接受標準,客戶可能就會選擇把整套訂單轉向其他供應商。這種動態凸顯了明確的機會:持續提升接受率可解鎖額外的市占增量,並擴大整體訂單捕獲率。
On slide 11, you'll see that we announced this morning that we will soon take a full range of sequences across length and complexity, driving towards accepting approximately 99.5% of chloro genes and 99.9% of all D&A products more broadly. With constant drive to improve sets us apart and importantly, more sequences accepted means more orders won and we intend to win them. And that matters because this is not a standardized market. Every customer is different. Every order is different.
在第 11 張投影片中,你會看到我們今早宣布:我們很快將能涵蓋跨長度與複雜度的完整序列範圍,目標是將 chloro genes 的接受率推進至約 99.5%,並將更廣泛的所有 D&A 產品接受率推進至 99.9%。持續精進的動能讓我們脫穎而出;更重要的是,接受的序列越多,就能贏得越多訂單,而我們打算把這些訂單贏下來。這之所以重要,是因為這不是一個標準化市場。每位客戶都不同,每張訂單也都不同。
Breadth drives share gain. It's that simple. In contrast to Twist, the competitive landscape has a pattern, niche players narrow offerings limited reach. That is not how customers operate and it is not how this market has won. We employ a different approach. We anchored our strategy around end applications where performance, scale and execution are the only metrics that matter.
廣度帶來市占提升,就這麼簡單。相較於 Twist,競爭格局呈現一種模式:利基型業者、產品供應狹窄、觸及範圍有限。但客戶的運作方式不是這樣,這個市場的致勝方式也不是這樣。我們採取不同的方法:以終端應用為策略錨點,在那裡真正重要的衡量標準只有效能、規模與執行力。
Customers do not want to stitch together multiple vendors. They want one partner who can deliver consistently across the workflow. That is where Twist is differentiated. We offer both depth and breadth across the biological continuum from perasynthesis through proteins, biologics and NGS. We support customers increasingly across the entire life cycle of their programs is how we continue to take share, expand wallet and reinforce our position to leading platforms, serving therapeutics, diagnostics, industrial, academic and government markets.
客戶不想把多家供應商拼接在一起。他們想要一個能在整個工作流程中穩定交付的合作夥伴。這正是 Twist 的差異化所在。我們在生物連續體上同時提供深度與廣度,從 perasynthesis 延伸到蛋白質、生物製劑與 NGS。我們愈來愈多地在客戶專案的全生命週期提供支援;這也是我們持續取得市占、擴大錢包份額並鞏固作為領先平台地位的方式,服務治療、診斷、工業、學術與政府市場。
With that, I'll turn it over to Adam to discuss the financials for the quarter.
接下來,我把時間交給 Adam,請他說明本季的財務表現。
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
Thank you. Turning to slide 12. Q2 is another quarter of consistent execution against the financial model we've laid out. Revenue grew 19.3% year-over-year to $110.7 million, our 13th consecutive quarter of sequential growth. Gross margin expanded to 51.6% versus the prior year, an improvement of approximately 200 basis points, and we remain firmly on track for adjusted EBITDA breakeven in Q4.
謝謝。請看第 12 張投影片。第二季是我們依照既定財務模型持續穩健執行的另一個季度。營收年增 19.3% 至 1.107 億美元,為連續第 13 個季度的季比成長。毛利率擴大至 51.6%,較去年同期提升約 200 個基點;我們也仍然堅定地朝向第 4 季調整後 EBITDA 損益兩平的目標前進。
Let me walk you through the details. On Slide 13, you'll see DNA synthesis and Protein Solutions revenue increased to $53.3 million, growth of 28% year-over-year. On slide 14, we show NHS applications revenue for the second quarter grew to approximately $57.4 million compared to $51.1 million in the second quarter of fiscal 2025, an increase of 12% year-over-year and up 9% sequentially, driven by growth in top accounts. For the quarter, revenue from our top 10 NHS applications customers accounted for approximately 39% and of NHS applications revenue. We serve 627 NHS applications customers in the quarter with 174 having adopted our products.
我來帶各位看細節。在第 13 張投影片中,你會看到 DNA 合成與蛋白質解決方案營收增加至 5,330 萬美元,年增 28%。在第 14 張投影片中,我們顯示第二季 NHS 應用營收成長至約 5,740 萬美元,相較於 2025 會計年度第二季的 5,110 萬美元,年增 12%,且季增 9%,主要由主要客戶成長所帶動。本季,我們前 10 大 NHS 應用客戶的營收約占 NHS 應用營收的 39%。本季我們服務 627 家 NHS 應用客戶,其中 174 家已採用我們的產品。
Looking geographically on slide 15. Americas revenue increased to approximately $64.3 million in the second quarter compared to $55.2 million in the same period of fiscal 2025. Growth of 17% year-over-year. EMEA revenue rose to $37.3 million in the second quarter versus $30.6 million in the same period of fiscal 2025, growth of 22% year-over-year. APAC revenue increased to $9.1 million in the second quarter compared to $7 million in the same period of fiscal '25, an increase of 30% year-over-year. APAC accounted for 8% of our revenue in the second quarter. China continues to be a relatively small portion of our revenue at approximately 1% of total revenue for the second quarter of fiscal 2020.
從地區來看(第 15 張投影片),美洲地區第二季營收增加至約 6,430 萬美元,較 2025 會計年度同期的 5,520 萬美元成長,年增 17%。EMEA 地區第二季營收升至 3,730 萬美元,較 2025 會計年度同期的 3,060 萬美元,年增 22%。APAC 地區第二季營收增加至 910 萬美元,較 2025 會計年度同期的 700 萬美元,年增 30%。APAC 在第二季占我們營收的 8%。中國仍占我們營收相對較小的部分,約為 2020 會計年度第二季總營收的 1%。
Looking at revenue by industry on slide 16. Therapeutics revenue rose to $40.8 million for the second quarter of 2026 compared to $26.3 million in the same period of fiscal '25, growth of 55% and reflecting the increased uptake of our products by large pharma and biotech customers in their efforts on therapeutic discovery and including AI-enabled discovery. Diagnostics revenue was $40 million for the second quarter of '26, compared to $35 million in the same period of fiscal 2025, an increase of 14%. Diagnostics revenue grew 13% versus Q1 of fiscal '26 based on strong growth from top accounts. Industry and applied revenue was $5.8 million in the second quarter '26 compared to $7 million in the same period of fiscal 2025.
按產業別來看(第 16 張投影片),2026 會計年度第二季治療領域營收上升至 4,080 萬美元,較 2025 會計年度同期的 2,630 萬美元成長,年增 55%,反映大型藥廠與生技客戶在治療探索(包括 AI 賦能探索)上對我們產品採用度提升。2026 會計年度第二季診斷領域營收為 4,000 萬美元,較 2025 會計年度同期的 3,500 萬美元增加 14%。診斷營收相較 2026 會計年度第一季成長 13%,主要來自主要客戶的強勁成長。工業與應用領域營收為 580 萬美元,較 2025 會計年度同期的 700 萬美元下降。
Academic research and government revenue was $12.8 million for the second quarter of '26 compared to $12.5 million in the same period of fiscal '25, an increase of 3%. And Sequential growth was 5% versus prior quarter, driven by strength in US accounts. Global Supply Partner revenue was $11.4 million in the second quarter of 2026, compared to $12 million in the same period of fiscal 2025, primarily due to order timing.
2026 會計年度第二季學術研究與政府營收為 1,280 萬美元,較 2025 會計年度同期的 1,250 萬美元增加 3%。相較前一季的季比成長為 5%,主要由美國客戶表現強勁所帶動。2026 會計年度第二季全球供應合作夥伴(Global Supply Partner)營收為 1,140 萬美元,較 2025 會計年度同期的 1,200 萬美元下降,主要由於訂單時點所致。
Moving down the P&L on slide 15. Our gross margin for the second quarter increased to 51.6%, an improvement of two margin points versus the same period of fiscal '25. Market expansion was driven by strong revenue growth and moderated sequentially as we continue to invest in new product offerings and manufacturing capacity that we expect will result in future margin gains as we accelerate growth and implement continuous process improvement.
接著看投影片 15 的損益表(P&L)。我們第二季的毛利率提升至 51.6%,較 2025 會計年度同期改善 2 個毛利率百分點。市場擴張主要由強勁的營收成長所帶動,但由於我們持續投資於新產品供應與製造產能,成長動能在序列上有所趨緩;我們預期這些投資將在我們加速成長並推動持續流程改善的同時,帶來未來的毛利率提升。
Operating expenses, excluding cost of revenues and litigation settlement costs were $95.8 million for the quarter compared to $87.6 million in the prior year. The increase reflects deliberate investment in our commercial organization and digital infrastructure to support the growth trajectory we are delivering, particularly the 55% growth in therapeutics. These are revenue-generating investments with a clear line of sight to return. We are managing these investments with discipline. In April, we reduced 36 positions to reallocate resources to our highest return opportunities. Combined with additional cost initiatives underway, we expect these actions to contribute to sequential OpEx improvement of $6 million in Q4 of fiscal '26.
營業費用(不含營收成本與訴訟和解成本)本季為 9,580 萬美元,去年同期為 8,760 萬美元。增加主要反映我們有意識地投資於商業組織與數位基礎設施,以支撐我們正在交付的成長軌跡,特別是治療(therapeutics)業務 55% 的成長。這些是能帶來營收的投資,且回收報酬具有清晰可見性。我們以紀律管理這些投資。4 月我們裁減 36 個職位,以將資源重新配置至報酬最高的機會。加上其他正在推進的成本措施,我們預期這些行動將在 2026 會計年度第 4 季帶來約 600 萬美元的序列 OpEx 改善。
Looking at our progress on our path to profitability. For the second quarter of fiscal 2026, adjusted EBITDA was a loss of approximately $13.3 million, an improvement of approximately $1.5 million versus the second quarter of fiscal '25. We have dramatically narrowed that loss through a combination of revenue growth, gross margin expansion and operating expense discipline. We expect the actions we've taken, combined with continued revenue momentum to fully deliver on our targets for Q4. We reached an agreement in principle regarding the securities class action for approximately $17.1 million.
再看我們邁向獲利的進展。2026 會計年度第二季,調整後 EBITDA 約虧損 1,330 萬美元,較 2025 會計年度第二季改善約 150 萬美元。我們透過營收成長、毛利率擴張與營業費用紀律的組合,已大幅縮小虧損。我們預期已採取的行動,加上持續的營收動能,將使我們在第 4 季完整達成目標。我們就證券集體訴訟達成原則性協議,金額約 1,710 萬美元。
In fiscal Q2, we booked $7.2 million for litigation settlement costs net recoveries as we expect the additional costs to be covered by our insurance. We view this as a positive resolution allowing management to remain fully focused on execution. We ended Q2 with $171.7 million in cash, cash equivalents and short-term investments versus $197.9 million as of December 31, 2025. The Sequential change reflects $17.6 million in operating cash usage, $7.9 million in CapEx as we continue to invest in manufacturing automation and $5 million in cash for the Invenra license and equity event.
在會計年度第 2 季,我們就訴訟和解成本(扣除回收)認列 720 萬美元,因我們預期額外成本將由保險承擔。我們視此為正向的解決方案,使管理團隊能持續專注於執行。第 2 季末,我們持有現金、約當現金與短期投資 1.717 億美元,相較於 2025 年 12 月 31 日的 1.979 億美元。序列變動反映:營運現金使用 1,760 萬美元、資本支出(CapEx)7.9 百萬美元(持續投資製造自動化),以及用於 Invenra 授權與股權事件的 500 萬美元現金。
On slide 18, turning to guidance. For fiscal 2026, we expect total revenue of $442 million to $447 million, growth of approximately 17% to 19%. We -- for Q3 of fiscal 2016, we expect total revenue of $114 million to $115 million, growth of approximately 19% year-over-year at the midpoint. As previously discussed, we expect NHS to be the driver of sequential growth in H2 and return to 20% by Q4. We remain confident in our trajectory and continue to forecast reaching adjusted EBITDA breakeven for the fourth quarter of fiscal 2026.
投影片 18,接著談展望。對於 2026 會計年度,我們預期總營收為 4.42 億至 4.47 億美元,約成長 17% 至 19%。我們——就 2016 會計年度第 3 季而言,我們預期總營收為 1.14 億至 1.15 億美元,以中位數計算年增約 19%。如先前所述,我們預期 NHS 將成為下半年(H2)序列成長的驅動力,並在第 4 季回到 20%。我們對成長軌跡仍具信心,並持續預測在 2026 會計年度第 4 季達成調整後 EBITDA 損益兩平。
With that, I'll turn the call back over to Emily.
接下來,我把電話交回給 Emily。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you, Adam. On slide 19, as we look ahead, we remain focused on delivering consistent measurable growth designed to scale over time. We see strong momentum across the port fill with continued growth in denseness and protein solutions, increasing adoption in AI-enabled discovery and a return to growth in NGS. We serve large and expanding markets where our platform is increasingly relevant. At the same time, our operating model continues to perform as expected.
謝謝你,Adam。投影片 19,展望未來,我們仍專注於交付一致且可衡量、並能隨時間擴張的成長。我們看到整體產品組合(port fill)動能強勁:denseness 與蛋白質解決方案持續成長、AI 賦能的探索(discovery)採用率提升,以及 NGS 重回成長。我們服務的市場規模龐大且持續擴張,我們的平台也愈來愈具相關性。同時,我們的營運模式持續如預期般運作。
We have delivered 13th consecutive quarters of sequential revenue growth, expanding gross margins above 50% and maintain a clear path to adjusted EBITDA breakeven in fiscal 2026. What opens this performance is the stability of our platform. As volume increases, we expand or improve efficiency and generate operating leverage across the business. Our ability to serve a wide range of customer workflows from early discovery through clinical and diagnostic applications provides both resilience and opportunity to capture more value over time.
我們已連續 13 個季度實現營收序列成長,毛利率擴張至 50% 以上,並在 2026 會計年度維持清晰的調整後 EBITDA 損益兩平路徑。支撐這項表現的是我們平台的穩定性。隨著量能增加,我們擴大規模或提升效率,並在全公司產生營運槓桿。我們能服務從早期探索到臨床與診斷應用的廣泛客戶工作流程,這同時帶來韌性與機會,使我們能隨時間捕捉更多價值。
Across the business, we invest with discipline we high return opportunities allocate capital deliberately underlying investments with clear growth drivers. We execute with focus and urgency to drive durable growth and build the company with increasing strategic resent and long-term value creation.
在整體業務上,我們以紀律投資,聚焦高報酬機會,並有意識地配置資本於具明確成長驅動因素的底層投資。我們以專注與緊迫感執行,以推動可持續的成長,並打造一家具有更強策略韌性與長期價值創造的公司。
With that, we're happy to take your questions.
接下來,我們很樂意回答各位的問題。
Operator
Operator
(Operator Instructions) Mac Etoch, Stephens.
(接線員指示)Mac Etoch,Stephens。
Steven Etoch - Equity Analyst
Steven Etoch - Equity Analyst
Maybe just to start, could you just discuss how AI-driven workflows performed in the quarter relative to your internal expectations? And how the change in the outlook for both of the segments is really contributing to the change in the updated fiscal guidance from here?
先從一個問題開始:能否談談本季 AI 驅動工作流程的表現,相較於你們內部預期如何?另外,兩個事業部展望的變化,如何實際促成你們更新後的會計年度財測指引的變動?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thanks for the question. Obviously, we're very excited with the performance of the SPS growing 28% year-over-year. And for the therapics category, we cracked the $40 million for the quarter. A lot of companies in the drug discovery field, they tap out at $50 million a year.
謝謝提問。顯然,我們對 SPS 年增 28% 的表現感到非常振奮。而在治療(therapics)類別方面,我們本季突破 4,000 萬美元。很多藥物探索領域的公司,一年做到 5,000 萬美元就到頂了。
And now, we're way past that. We're almost there every quarter. So obviously, there is the trend throughout the menu. What we see is that customers don't want one thing -- and so the NPI engine that we built that creates a lot of options for people to enter as it's been a great driver. And obviously, AI-driven drug discovery has been a big help in that area. It just increases the number of sequences that people want to look at.
而現在,我們早已超過那個水準;幾乎每一季都快達到。因此,整個產品選單(menu)都呈現趨勢性成長。我們看到客戶不只想要單一產品——因此我們建立的 NPI 引擎,能創造許多選項讓客戶切入,成為很大的驅動力。當然,AI 驅動的藥物探索在這方面也幫了大忙,因為它只是增加了人們想要查看的序列數量。
If we look sequence before, now with AI, they can get thousands. And so it just increases the overall value of the deals. And a lot of companies don't have the capacity to analyze that number of antibodies. And so it enables us to upscale upsell to data and cell coradiation. So overall, the entire menu is doing well, but hydro discovery has definitely been great sales in -- great wins in our sales.
以前如果看序列,現在有了 AI,他們可以得到成千上萬個。因此它提高了交易的整體價值。很多公司沒有能力分析那麼多抗體,所以這也讓我們能向上擴展、向上銷售到資料與細胞 coradiation。整體而言,整個選單表現都很好,但 hydro discovery 確實在——在我們的銷售上帶來了很好的成交——很好的勝出案例。
Operator
Operator
Vijay Kumar, Evercore ISI.
Vijay Kumar,Evercore ISI。
Vijay Kumar - Equity Analyst
Vijay Kumar - Equity Analyst
Congrats on a nice (inaudible). Maybe on the prior question rate related to -- when I look at the up 55% in the second quarter. That's an acceleration from Q1 growth levels. How much of this acceleration was driven by AI-related programs. I think in the past, memory called data characterization genes versus traditional biopharma and when you look at back half, is this 50% kind of growth sustainable when you look at your order book and backlog?
恭喜有個不錯的(聽不清)。延續前一題、關於——當我看到第二季年增 55% 時,這相較 Q1 的成長水準是加速的。這個加速有多少是由 AI 相關專案所驅動?我想過去你們提到過,記憶中是把資料表徵(data characterization)類型的基因與傳統生物製藥做區分;那麼看下半年,從你們的訂單簿與積壓訂單(backlog)來看,這種 50% 左右的成長是否可持續?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
That's a great question. Definitely, AI has been a source of strength. Again, the nice thing as people develop more sequences, which have levels of DNA, we can make if they want a pool library of EHS, we can make it if they want. Even for biospecific now we can improve. We can make the flavor of the SG&A on pool. So that's -- so the entry point of whatever they want that broad menu, they're useful. -- but with AI, as I mentioned earlier, there is more need for data characterization.
這是個很好的問題。AI 的確是強勁來源。再說一次,好的地方在於,當人們開發出更多序列(具有 DNA 的層級),我們都能製作:如果他們想要一個 EHS 的 pool library,我們可以做;如果他們想要的話。甚至現在對於雙特異性(bispecific),我們也能改進。我們可以做 pool 上的 SG&A 風味。因此——無論他們想要什麼,那個廣泛的選單都是有用的。——但有了 AI,如我先前提到的,對資料表徵的需求更高。
And what has happened is maybe in 2025, there was excitement definitely on our side. But that excitement came from very few number of accounts and now that we are many quarters into this, now it's dozens of accounts that are driving the growth, right? It's not just a few. And so we can see that is repeatable with the existing account, but we're able to bring more and more people into the fold. And then sometimes, we can enter through AI-driven with discovery, but a lot of those companies are doing both AI-driven drug discovery and traditional drug discovery and the fact that we have a full menu enables us to grow in all areas.
而發生的情況是,也許在 2025 年,我們這邊確實很興奮。但那份興奮來自非常少數的客戶帳戶;而現在我們已經走過很多個季度,推動成長的是數十個帳戶,對吧?不再只是少數幾個。因此我們可以看到,這在既有帳戶中是可重複的,同時我們也能把越來越多的人帶進來。有時我們可以從 AI 驅動的探索切入,但很多公司同時在做 AI 驅動藥物探索與傳統藥物探索,而我們擁有完整選單的事實,使我們能在各個領域成長。
So overall, is broad-based. Going forward, we are not guiding per product groups. I think there's very good growth potential within the business. And we doubled, the raise is double the beat, right? So obviously, there's a lot of confidence. But that confidence is broad-based. And we also share some strong confidence for our NHS business. So the business is reaping. The sales team is confident customers are happy. So we just have to do it again.
所以整體而言,是廣泛分布的。往前看,我們不再按產品群組提供指引。我認為公司內部有非常好的成長潛力。而我們把上調幅度加倍,這次上調是超預期(beat)的兩倍,對吧?所以顯然信心很高。但這份信心是廣泛的。我們也對 NHS 業務分享了很強的信心。因此業務正在收穫成果。銷售團隊有信心、客戶也很滿意。所以我們只需要再做一次。
Operator
Operator
Doug Schenkel, Wolfe Research.
Doug Schenkel,Wolfe Research。
Doug Schenkel - Equity Analyst
Doug Schenkel - Equity Analyst
I want to just cover two topics, the academic and government end market and then gross margin. So in A&G, what are you seeing? Are things stabilizing or improving? Just want to get a sense for how things are trending. And are you still running the academic promotion on express genes and kind of building off of that, when do we start to lap the headwinds on price per gene from express gene fragments. I think that's this summer? So I just want to be mindful of that as we're updating our models.
我想涵蓋兩個主題:學術與政府(academic and government)終端市場,以及毛利率。先談 A&G,你們看到什麼?情況是在穩定還是在改善?我想了解趨勢如何。另外,你們是否仍在對 express genes 進行學術促銷並在此基礎上延伸?以及我們何時開始跨過(lap)每基因價格(price per gene)因 express gene fragments 所帶來的逆風?我想是在今年夏天?所以在我們更新模型時,我想留意這點。
And then a quick on on gross margin. Gross margin was down nominally sequentially and a little bit light of our model and street models. That just may be in the noise, but wanted to see if there's anything to call out there.
接著快速談一下毛利率。毛利率在名目上較前一季略降,且比我們的模型以及華爾街的模型稍微低一些。這可能只是雜訊,但想確認是否有任何需要特別說明的地方。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Okay. Yes. So maybe I'll take the first question and Adam will cover the second one. Yes, on academic, definitely that end market is suffering from funding pressures. Our approach is to take market share.
好的。是的。所以也許我先回答第一個問題,Adam 會回答第二個。是的,在學術端,該終端市場確實正承受資金壓力。我們的做法是搶市占。
And so academic the -- when funding is a pressure, they are very cautious because they are dollars. And so especially, that market is basically shrinking right now. So the fact that we are growing and growing sequentially is definitely a good thing. It shows that our product offering resonates more than the competition.
因此在學術端——當資金成為壓力時,他們會非常謹慎,因為每一分錢都很重要。尤其是,這個市場目前基本上正在萎縮。所以我們能夠成長、而且還能逐季成長,絕對是件好事。這顯示我們的產品組合比競爭對手更能引起共鳴。
And so right now, we are very happy to extend the premium discount for what that enables economic people to get (inaudible) genes at the price of standard lens. And so they get a great value on the DNA they're seeing from us. They're getting great speed. It enables them to go faster and get better at their next brand and knowing that those brands are very competitive. So I think our discount is very well received by those customers. And definitely, the growth there is smaller than for industry segment. but we are taking market share.
因此目前,我們很高興延長這個「高階折扣」,因為這讓經濟型客戶能以標準鏡頭的價格取得(聽不清)基因。也就是說,他們從我們這裡看到的 DNA 具有很高的價值;他們也獲得很快的速度。這讓他們能更快推進,並在下一個品牌上做得更好,且我們知道那些品牌競爭非常激烈。所以我認為,我們的折扣在這些客戶之間反應非常好。而且,該處的成長確實比產業端小,但我們正在搶市占。
Adam, you want to cover the gross margin question?
Adam,你要回答毛利率的問題嗎?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
No, absolutely. Welcome, everyone. And Q2 definitely reflects a deliberate investment, specifically for IgG and characterization for a discovery projects. as well as our digital capabilities. We remain confident in our 52% or better guide for the year.
當然。各位好。第二季確實反映了我們有意識的投資,特別是針對 IgG 與發現型專案的特性鑑定,以及我們的數位能力。我們仍然有信心維持全年 52% 或更高的指引。
And this investment is really around adding capacity of people to support the accelerated demand. We see a huge ROI on it. And we also see the path to continuously making improvements on those efforts in new products and returning to a 75% to 80% average drop through on incremental revenue to gross margin, as we move forward and automate workflows.
而這項投資主要是增加人力產能,以支援加速成長的需求。我們看到非常高的投資報酬率(ROI)。同時,隨著我們持續自動化工作流程,我們也看得到持續改善這些工作、推出新產品的路徑,並在未來把增量營收對毛利率的平均落袋率(drop-through)拉回到 75% 到 80%。
Operator
Operator
Luke Sergott, Barclays.
Luke Sergott,Barclays。
Luke Sergott - Analyst
Luke Sergott - Analyst
Just a couple here. I want to follow up on Doug's question there. When you -- Adam, when you're talking about the gross margin improvement and the kind of the automated workflows, like what -- you guys have just built out the new facility. It's pretty state-of-the-art from what you had previously. So talk about further investment or how much more you guys can continue to push that automated workflow.
我這邊有兩個問題。我想追問一下 Doug 剛剛的問題。Adam,當你談到毛利率改善以及自動化工作流程時——你們剛建好新廠,跟以前相比看起來相當先進、很符合最新水準。請談談後續還要再投資什麼,或你們還能在多大程度上持續推進這些自動化工作流程。
And then I wanted to follow up and ask more on the data characterization of the AI projects. You guys talked about $25 million in bookings in 4Q coming from some of these AI projects. How much of the revenue in the first 6 months of the year has been converted from that? Or like is that still a majority on the comp?
另外我也想追問 AI 專案的資料特性鑑定。你們提到去年第四季有 2,500 萬美元的訂單(bookings)來自其中一些 AI 專案。今年前 6 個月有多少營收已經從那部分轉換出來?或者那仍然是比較大宗、仍在可比基期(comp)裡嗎?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thanks for the question. So maybe I start with the first one, and you guys are really good to squeezing two questions into one, but (inaudible). So on the first one, as you (inaudible) at the front end and the back end, right? So the front end is a shift. That's where we make the oligos, -- that's where we get the massive advantage.
謝謝你的問題。所以也許我先回答第一個——你們真的很擅長把兩個問題塞進一個問題裡,但(聽不清)。第一個部分,如你(聽不清),有前段與後段,對吧?前段是一個轉換點。那是我們製作寡核苷酸(oligos)的地方——也是我們取得巨大優勢的地方。
And then after the vials are made, depending on the flavor, it goes to different back-end. So in general, the back end for our GSPS is a different back end for NGS. And then in the (inaudible) solution, we first make a fragment and then some stop there, they get shipped. Then we make clonal genes, some stop there, make a chip, and then we make IgG expressions and stop the bigger chip and then some of the agility gets characterized.
然後在小瓶(vials)製作完成後,依不同產品類型(flavor),會進到不同的後段流程。一般來說,我們 GSPS 的後段流程與 NGS 的後段流程不同。而在(聽不清)解決方案中,我們先做片段(fragment),有些在那一步就停止並出貨;接著我們做克隆基因(clonal genes),有些在那一步就停止;再來做晶片(chip);然後做 IgG 表達並停在更大的晶片;最後其中一部分(聽不清)會進行特性鑑定(characterized)。
And so as you can imagine, as we add flavor, we have to add a little bit of automation to add capacity for that new flavor. So it's not a tremendous amount of CapEx. I mean it's significant, but compared to building a new fab from scratch, it's not comparable. And so that's the strategy we've been using is showing the demand from customers and adding a little bit of automation on the back end on the branch that's needed. So that's one.
因此你可以想像,當我們增加新的產品類型時,就必須增加一些自動化來為該新類型擴充產能。所以資本支出(CapEx)不會是非常巨大的量——我的意思是它是顯著的,但跟從零開始蓋一座新晶圓廠(fab)相比,完全不可同日而語。因此我們一直採用的策略是:先看到客戶需求,然後在需要的那個後段分支上,增加一點自動化來擴充產能。這是第一點。
And then the other thing we've done is we've been automating the automation. And so for those of you that come to our Investor Day you'll see that the giant room, we are now in that 1 room, we've been able to automate the automation and now we we'll be able to have multiple times the capacity that we used to have in that room. In terms of your second question around the $25 million of orders that we had last year, those have all been shipped now -- most of that was finished by Q1 and very little impact of that in Q2.
第二點是,我們一直在把「自動化」再自動化。對於會來參加我們投資人日的人,你們會看到那個大房間——我們現在都在那一個房間裡;我們已經能把自動化再自動化,現在我們將能在那個房間裡達到過去數倍的產能。至於你第二個問題,關於去年那 2,500 萬美元的訂單,現在都已經出貨了——其中大部分在第一季就完成了,第二季受到的影響非常小。
As you remember, one thing that that's a key differentiation from us is the speed at which we deliver data. And so some data -- most of the data is delivered 15 to 20 days after we receive the sequence. It's a quick turnaround to book the reps.
如你所記得,我們的一個關鍵差異化在於交付資料的速度。因此有些資料——大多數資料——在我們收到序列後 15 到 20 天就會交付。這是很快的周轉時間,能讓業務代表快速完成訂單入帳(book)。
Operator
Operator
Subbu Nambi, Guggenheim.
Subbu Nambi,Guggenheim。
Subbu Nambi - Equity Analyst
Subbu Nambi - Equity Analyst
You increased your full year revenue guidance by more than the magnitude of the Q2 beat. Any specific area or areas which drove the increase, essentially, I'm asking for coverage.
你們把全年營收指引上調的幅度,超過第二季超預期(beat)的幅度。是哪些特定領域推動了這次上調?本質上,我是在問:這次上調的涵蓋面(coverage)是什麼?
Luke Sergott - Analyst
Luke Sergott - Analyst
What we talked about in the back half, while sequentially, most of the improvements are going to come from NHS -- if you look at the full year guide, you can see that, that implies that the DSPS is really the strength of the raise in the back half. So if you are modeling it out, sequentially, we don't expect anything to go backwards in terms of DSPS. We only expect continued increases in the overall revenue, but at a more modest rate. And again, it really is dependent upon the pace of us getting new customers into the DSS side and the ability to potentially exceed those expectations will -- is an area of opportunity for us. .
我們談到下半年時,雖然就逐季來看,多數改善會來自 NHS——但如果你看全年指引,你會看到那其實意味著 DSPS 才是下半年上調的主要動能。因此如果你在建模,逐季來看,我們不預期 DSPS 會有任何倒退。我們只預期整體營收會持續增加,但增速會更溫和一些。再者,這真的取決於我們把新客戶導入 DSS 端的速度;而在這方面,若能潛在地超越那些預期——將會是我們的機會所在。.
Operator
Operator
Matt Larew, William Blair.
Matt Larew,William Blair。
Matt Larew - Analyst
Matt Larew - Analyst
I wanted to ask on the complex DNA offering. So what's the time line at which you expect to deliver products sort of in line with the capabilities you described today, what lengths do you expect to be able to get up to in terms of manufacturing? And do you have any sense or could you give us a sense or what the missed opportunity has been a story. You referenced, I think in some cases, losing a whole order because you couldn't make a sequence. So what kind of additional opportunity does this unlock by adding these new capabilities?
我想問關於複雜 DNA 產品。你們預期在什麼時間軸上,能交付與你們今天描述的能力相符的產品?在製造長度方面,你們預期能做到多長?另外,你們是否能讓我們了解一下過去錯失的機會有多大?你提到我想在某些情況下,因為你們無法製作某個序列而失去整筆訂單。新增這些能力後,會解鎖什麼樣的額外機會?
Patrick Finn - President, Chief Operating Officer
Patrick Finn - President, Chief Operating Officer
Matt, it's Paddy here. Thanks for the question. We're pretty excited about the product. I think you could hear from my comments, retinal we accept the vast majority of sequences that come our way across all of the portfolio. And there is a few percentage business or a few percentage points in sequence we don't take, which we see some instances where the customer wants to take that total order somewhere else.
Matt,我是 Paddy。謝謝你的問題。我們對這個產品非常興奮。我想你從我的評論中也聽得出來,目前我們在整個產品組合中,能接受絕大多數送到我們這裡的序列。仍有少數幾個百分點的業務、或少數幾個百分點的序列我們不承接;而我們確實看到一些情況是,客戶會因此把整筆訂單轉到其他地方。
The trends that emerging nucleic acid therapeutics and plant engineering and, of course, AI, they have some special needs or special requirements arriving then the sequence complexity. . And so true to auction, we're focused on the customer experience. Our goal is to create a one-stop shop when you leverage our DNA synthesis platform that can print really high-quality DNA. And just as a reminder, up to approximately $1 billion per ,that gives us super quality, speed and economics of scale, including for complex sequence.
新興趨勢如核酸治療、植物工程,當然還有 AI,它們在序列複雜度方面有一些特殊需求或特殊要求。 . 因此一如既往,我們聚焦在客戶體驗。我們的目標是:當你使用我們的 DNA 合成平台時,打造一站式服務,能印製出非常高品質的 DNA。也提醒一下,我們的規模大約可達每年約 10 億美元的(聽不清),這讓我們具備卓越品質、速度與規模經濟,包括針對複雜序列。
And so now with a little bit more optimization throughout the entire workflow, it's going to deliver products best-in-class. So broad sequence acceptance really strong, predictable and transparent performance when you're on the Twist platform to its reliability.
因此,現在透過對整個工作流程做更多優化,我們將能交付同級最佳(best-in-class)的產品。也就是:廣泛的序列接受度非常強、在 Twist 平台上具備強而可預測且透明的表現,以及其可靠性。
Our platforms industry aligned, it's faster, cheaper, strong best-in-class customer us-- sorry, e-comm user experience, then you've got Twist customer service and support, so that's trained scientists to understand the customer's experiment there to help the customer through any of their challenges. So there's a lot to like with the offering. And we're looking forward to scaling in the coming few quarters. So we're talking about early access start with a sort of classic to make a few customers happy and learn as we grow and you'll continue to see the capability of ramp up as we go through the quarters.
我們的平台與產業需求對齊,速度更快、成本更低,並提供同級最佳的客戶——抱歉,是電商(e-comm)使用者體驗;再加上 Twist 的客戶服務與支援,也就是受過訓練的科學家,能理解客戶的實驗,協助客戶解決各種挑戰。因此這個產品有很多值得期待之處。我們也期待在接下來幾季擴大規模。我們會先以 early access 的方式開始,先讓少數客戶滿意並在成長中學習;你也會在接下來各季持續看到我們的能力逐步爬升。
Operator
Operator
Catherine Schulte, Baird.
Catherine Schulte,Baird。
Catherine Schulte - Analyst
Catherine Schulte - Analyst
Maybe on the margin side, still on target to hit adjusted EBITDA breakeven in the fourth quarter. you've been very prescriptive about gross margin incrementals. I guess as you hit that milestone, how should we think about leverage beyond that point and maybe EBITDA margin incrementals going forward? .
也許從利潤率的角度來看,仍然按計畫在第四季達到調整後 EBITDA 損益兩平。你們對毛利率增量一直講得很具體。我想問,當你們達到那個里程碑時,我們應該如何看待在那之後的槓桿效應,以及未來 EBITDA 利潤率增量的走勢?
Adam Laponis - Chief Financial Officer
Adam Laponis - Chief Financial Officer
Thank you for the question. In terms of where we are today or laser-focused on making sure we cross the adjusted EBITDA positive here while also, at the same time, ensuring the maximum acceleration of revenue growth. So it's really titrating that investment in such a way that we maximize growth rates. As we go forward, we have optionality. We talked about that before.
謝謝你的提問。就我們目前的狀況而言,我們非常聚焦於確保在這裡跨過調整後 EBITDA 轉正,同時也要確保營收成長能夠最大幅度加速。因此,關鍵在於以一種能夠最大化成長率的方式來精準調配投資。往後看,我們有選擇權。我們之前也談過。
We'll talk about it more in the future. But we're steward to the market, and we understand that our continued path of not going backwards is very important to us and also ensuring that we continue to sustain the accelerated levels of growth. So those will be the two focus areas. And I think we'll spend some more time talking about that at our Investor Day here coming up.
我們未來會再多談一些。但我們對市場負有責任,也理解我們持續前進、不走回頭路的路徑對我們非常重要,同時也要確保我們能持續維持加速的成長水準。所以這將是兩個重點。我想我們會在即將到來的投資人日上花更多時間談這些。
Operator
Operator
Puneet Souda, Leerink Partners.
Puneet Souda,Leerink Partners。
Unidentified Participant
Unidentified Participant
You have Michael on for Puneet. Congrats on the quarter. I was hoping to get some color on the jeans. So I saw a strong growth in the physical gene shift. Last quarter, you talked about 58% for characterization. I was wondering if you could offer any color on the contribution of gene per productization this quarter? And if you could offer any insight to us on how much of this ad demand is driven by more model building versus the incorporation of AI into your ongoing drug discovery, lead generation work at pharma?
我是代替 Puneet 的 Michael。恭喜本季表現。我想多了解一下基因(genes)方面。我看到實體基因轉換(physical gene shift)成長很強。上季你們提到表徵(characterization)占 58%。我想請問本季每個產品化基因(gene per productization)的貢獻能否提供一些說明?另外,也想請教:這些廣告需求(ad demand)有多少是由更多模型建構所驅動,相較於製藥端在既有藥物發現、先導物生成工作中把 AI 納入流程所帶來的需求?
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you. Great question. We did not share the numbers today. We were trying to straddle the fine line between being as transparent to indisposable and not keeping the competition too much. I'm sure some of them are on the line today. Now what we can say is that it's more, right? So there definitely growth in many genes where internally to generate data that was sold. So definitely, to be definitely the growth there.
謝謝。這是個很好的問題。我們今天沒有分享那些數字。我們試著在盡可能透明、對投資人負責,與不讓競爭對手掌握太多之間取得平衡。我相信今天有些競爭對手也在線上。我們能說的是:更多了,對吧?所以確實在許多基因上有成長,我們內部產生的資料也有對外銷售。因此,那裡的成長是確定存在的。
And the second -- there was a second question.
第二個——還有第二個問題。
Unidentified Participant
Unidentified Participant
Yes. It was around the ability to how much of the growth is coming from making the model.
是的,是關於成長有多少來自於建模。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
I'm sorry, on the number. Yes, very interesting, actually, -- we're seeing a lot of customers that have shifted while the beginning was bidding model. I think by now, most of them or a lot of them are now turning the crank. And so when they turn to crank, what we see is that the orders maybe each order may be a little bit smaller. So billion model is a big bolus upfront, it's a little bit smaller, but it's more of it. And so we are very pleased to see that people are returning -- and yes, it's working as expected. It's working well.
抱歉,關於數字。是的,這其實很有意思——我們看到很多客戶已經轉變:一開始是在建模。我想到了現在,他們大多數或其中很多已經開始「持續運轉」(turning the crank)。當他們開始持續運轉時,我們看到的是訂單可能每筆會小一些。建模是一開始很大一筆(big bolus upfront),之後會小一些,但頻率更高。因此我們很高興看到大家回來——是的,運作如預期,效果很好。
Operator
Operator
Brendan Smith, TD Cowen.
Brendan Smith,TD Cowen。
Brendan Smith - Analyst
Brendan Smith - Analyst
Maybe just to put a pin in the AI or just questioning here fully. I guess, looking at that $25 million from last year, do you have a sense or can you tell us what kind of run rate you're looking at now for like '26, maybe just with the first half on your belt. And I guess related to that, and within those revenues, I guess, can you give us a sense what the relative breakdown between revs from oligos versus IgG versus analytical data? Just kind of wondering really how much is the area mostly done, kind of further down that funnel or really where they're shaking out?
也許把 AI 的問題先釘住、把這部分問完整。我想,回頭看去年那 2,500 萬美元,你們是否有概念或能否告訴我們,現在對於像 2026 年的年化運行率(run rate)大概看到多少——尤其是上半年已經過去之後?另外,相關地,在這些收入裡,你們能否說明一下來自寡核苷酸(oligos)對比 IgG 對比分析數據(analytical data)的相對拆分?我主要想了解這個領域到底多大程度已經在漏斗後段完成,或目前大致落在哪些環節。
Patrick Finn - President, Chief Operating Officer
Patrick Finn - President, Chief Operating Officer
I can start with a little bit of color around how to think about where we're going. If you think about the therapeutics segment as a whole, obviously, the AI discovery is falling in there. And if you look at the outsized growth versus the average of the business, that delta is predominantly AI discovery work. I will say, at times, it's hard to know exactly whether it's a discovery or class of work. We don't always know exactly the number as well as whether it's training or building the models. But pretty strong confidence that the vast majority of at growth in therapeutic advance scope. I want to hand it to a second half.
我可以先補充一些方向性的說明,談談我們如何看待未來。如果你把治療(therapeutics)部門整體來看,顯然 AI 發現(AI discovery)就落在其中。而如果你看相對於公司平均業務的超額成長,那個差額主要就是 AI 發現工作。我會說,有時候很難精確判斷到底是發現類工作,還是某一類別的工作。我們也不一定總能精確知道數字,以及它究竟是訓練模型還是建構模型。但我們相當有信心,治療相關的擴展範圍(therapeutic advance scope)成長的絕大部分來自 AI 發現。我想把後半段交給(下一位)。
Operator
Operator
Tom DeBourcy, Nephron Research.
Tom DeBourcy,Nephron Research。
Thomas DeBourcy - Equity Analyst
Thomas DeBourcy - Equity Analyst
Diagnostics as a whole and the double-digit growth and also double-digit sequential growth as sort of you had, I guess, projected before. Just as you think about the rest of the year, do you see incremental sequential growth through Q3, Q4? Just thinking about diagnostics customers and their contribution to NGS.
診斷(Diagnostics)整體呈現雙位數成長,而且也如你們先前預期,呈現雙位數的季增。展望今年剩餘時間,你們是否預期在第三季、第四季仍會有額外的逐季成長?主要想從診斷客戶及其對 NGS 的貢獻來思考。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
Thank you, Tom. Yes, definitely, we are seeing growth. I think we in Q4, we're experiencing at least 1% growth in NHS alone. And it's a good reminder. We talked a lot on the call of our DNA synthesis and protein solution and AI discovery, we love it all.
謝謝你,Tom。是的,確實,我們正在看到成長。我想在第四季,我們僅在 NHS 就至少經歷了 1% 的成長。這也提醒大家:我們在電話會議中談了很多 DNA 合成、蛋白解決方案以及 AI 發現——我們都很喜歡。
At the same time, it's a good reminder that dollar growth in NHS or dollar growth in DNA synthesis and Protein solution is very similar to us. And so what we are optimizing for as a management team. for revenue growth for the entire business. gross margin above 50% and getting to adjusted EBITDA breakeven. And so -- and the portfolio of panels that is the library prep that we built in the NHS application group enables us to sustain great growth. We are liquid biopsy customers, our MRD customers ramping and adopting. And so we are very definitely very confident in that part of the business.
同時,這也提醒大家,NHS 的美元成長,或 DNA 合成與蛋白解決方案的美元成長,對我們而言非常相近。因此,作為管理團隊我們正在優化的是:整體業務的營收成長、50% 以上的毛利率,以及達到調整後 EBITDA 損益兩平。因此——而我們在 NHS 應用團隊所建立的 panel 組合(也就是文庫製備 library prep)使我們能夠維持很好的成長。我們的液體活檢客戶、MRD 客戶正在爬坡並採用。因此,我們對這部分業務非常、非常有信心。
And we are very much looking forward to return growth -- they were not so long ago, it was flipped where we had 28%-ish growth in NHS and 12% growth in DNA synthesis and protein solutions, it's going to flip-flop back and forth. But at the end of the day, what matters to us is the entire business out growth in float into the life science tools industry hopefully, we are unique in the kind of growth that we are being able to post, not just this quarter, but by now certain quarters in a row. So [$110.7 million] this quarter and not so long ago, we had $19 million for the entire year, right? So we'll keep doing it. And I think the future is very bright.
而且我們非常期待成長回歸——不久之前其實是相反的:NHS 約 28% 的成長、DNA 合成與蛋白解決方案 12% 的成長;它會來回交替。但歸根結底,對我們重要的是整體業務的超額成長,並在生命科學工具產業中脫穎而出。希望我們在能夠交出的成長類型上是獨特的,不只是這一季,而是到現在已經連續好幾季。這一季是 [$110.7 million],而不久之前,我們全年才 1,900 萬美元,對吧?所以我們會繼續做下去。我認為未來非常光明。
Operator
Operator
Thank you. There are no further questions. At this time, I'd like to turn the call back over to Emily Leproust for closing remarks.
謝謝。目前沒有其他問題。此時我想把電話交回給 Emily Leproust 作結語。
Emily Leproust - Chairman of the Board, Chief Executive Officer
Emily Leproust - Chairman of the Board, Chief Executive Officer
As we wrap up, we look forward to continuing the competition in person at our Investor Day on May 21 in Oregon. This will be an incredible opportunity to go deeper into the drivers behind our performance cleared directly from our customer in Twist across therapy discovery NHS workload and participate in a tool that brings our platform to life. We will also have the chance to engage with members of our management team as we discuss how we are scaling the platform, expanding into new applications and driving long-term value creation. See you there. Thank you.
在我們結束之前,我們期待在 5 月 21 日於俄勒岡州舉行的投資人日與各位線下見面,並持續競爭。這將是一次絕佳機會,讓我們更深入探討驅動我們表現的因素,並直接聽取我們在 Twist 的客戶在治療發現、NHS 工作量方面的分享,並參與一個讓我們平台具體呈現的工具。我們也將有機會與管理團隊成員交流,討論我們如何擴大平台規模、拓展到新的應用,並推動長期價值創造。到時見。謝謝。
Operator
Operator
Thank you for your participation. You may now disconnect. Good day.
感謝您的參與。您現在可以斷線。祝您有美好的一天。